ReproNovo ApS

Based in Switzerland, ReproNovo ApS engages in developing innovative therapeutic solutions aimed at enhancing reproductive medicine and women's health, particularly addressing infertility challenges. ReproNovo ApS focuses on advanced therapeutic approaches within reproductive health. Founded in 2021 in Lausanne, Switzerland. In May 2025, ReproNovo ApS raised EUR 57 million in series A funding co-led by Jeito Capital, AXA IM Alts and M Ventures, with participation from Ysios Capital Partners and ALSA Ventures.

ReproNovo specializes in innovative therapeutic solutions focused on improving reproductive medicine and women's health. The company’s core product offerings include treatments for male and female infertility, as well as pioneering options for conditions such as adenomyosis, a complex uterine disorder. These products are designed to enhance success rates in assisted reproductive technologies, addressing critical gaps in the current treatment landscape. ReproNovo's solutions are aimed at individuals facing infertility challenges, with a significant focus on providing effective alternatives where traditional treatments are limited or non-existent.

The company's products are marketed primarily in Europe, with ongoing efforts to expand their reach in international markets, thereby serving a diverse client base of healthcare providers and patients seeking reproductive health solutions. ReproNovo generates revenue through collaborations and partnerships with various healthcare institutions and investors committed to advancing reproductive health. The company engages in business-to-business transactions, ensuring that its innovative therapies reach clinics and fertility specialists who utilize these products in patient treatments. Revenue streams are structured around licensing agreements and distribution partnerships, allowing healthcare providers to integrate ReproNovo's therapies into their offerings.

The company’s flagship services are expected to be part of comprehensive treatment packages that healthcare providers offer to patients seeking assistance with infertility and related conditions. In May 2025, ReproNovo ApS raised EUR 57. 000 mn in Series A funding, which will be utilized to support the further development of its pipeline of therapeutic solutions. The company aims to expand into new markets, specifically targeting broader European markets and other international regions, to enhance access to their innovative reproductive health solutions.

Upcoming product launches are expected to focus on advanced treatments for infertility and related conditions, although specific release dates have yet to be disclosed.